Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up – Time to Buy?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares gapped up before the market opened on Wednesday . The stock had previously closed at $17.61, but opened at $19.76. Sarepta Therapeutics shares last traded at $22.2830, with a volume of 6,241,387 shares changing hands.

More Sarepta Therapeutics News

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Company published encouraging early Phase 1/2 data for SRP‑1001 (FSHD1) and SRP‑1003 (DM1): dose‑dependent muscle exposure, early biomarker effects and favorable tolerability — potential to open new rare‑disease franchises and justify re‑rating. Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
• Positive Sentiment: Market reaction: outlets reported a ~20% intraday gain after the data release, reflecting short‑term buying and renewed investor interest in Sarepta’s diversified pipeline beyond its traditional exon‑skipping and micro‑dystrophin assets. Sarepta Therapeutics Zooms 20% Higher on Promising Clinical Data: Is SRPT Ready for a Bigger Breakout?
• Neutral Sentiment: The company hosted/announced a webcast to present the data (investors should review the webcast/transcript for read‑throughs on biomarker durability, safety and next trial steps). Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
• Neutral Sentiment: Short‑interest reporting in the feed showed anomalous “0 shares” entries for March (data appears unreliable); not a clear signal of crowd positioning.
• Negative Sentiment: Fundamentals and valuation risks remain: Sarepta recently reported a large EPS miss, negative margins and revenue declines year‑over‑year — any enthusiasm will be weighed against execution risk, commercialization performance of existing products, and cash/runway considerations.
• Negative Sentiment: Analyst/market skepticism about valuation persists — commentary has framed the company as under‑priced relative to its business potential, which can limit the upside if upcoming data or commercial metrics don’t show clear progression. Sarepta Therapeutics: A $2B Business Priced Like It’s Broken

Analyst Upgrades and Downgrades

Several research firms recently issued reports on SRPT. HC Wainwright reissued a “sell” rating on shares of Sarepta Therapeutics in a research note on Monday, March 2nd. Wall Street Zen upgraded Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Barclays began coverage on Sarepta Therapeutics in a report on Wednesday, January 28th. They issued an “equal weight” rating and a $20.00 price target on the stock. Citigroup lifted their price target on Sarepta Therapeutics from $8.00 to $9.00 and gave the company a “sell” rating in a research report on Tuesday, March 10th. Finally, Mizuho upped their price objective on shares of Sarepta Therapeutics from $26.00 to $31.00 and gave the stock an “outperform” rating in a research report on Thursday, March 12th. Nine equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $32.15.

Sarepta Therapeutics Stock Performance

The company has a 50 day simple moving average of $18.68 and a 200-day simple moving average of $19.94. The company has a debt-to-equity ratio of 0.73, a current ratio of 2.32 and a quick ratio of 1.48. The stock has a market cap of $2.37 billion, a P/E ratio of -2.68, a price-to-earnings-growth ratio of 0.28 and a beta of 0.42.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported ($3.58) EPS for the quarter, missing the consensus estimate of ($0.87) by ($2.71). The firm had revenue of $442.93 million for the quarter, compared to the consensus estimate of $390.95 million. Sarepta Therapeutics had a negative net margin of 38.34% and a negative return on equity of 50.74%. Sarepta Therapeutics’s revenue for the quarter was down 32.7% compared to the same quarter last year. During the same quarter last year, the company posted $1.90 earnings per share. On average, equities analysts expect that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Stephen Mayo sold 7,239 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $17.02, for a total transaction of $123,207.78. Following the transaction, the director directly owned 1,765 shares of the company’s stock, valued at approximately $30,040.30. This trade represents a 80.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 7.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of institutional investors have recently made changes to their positions in the business. AQR Capital Management LLC increased its holdings in shares of Sarepta Therapeutics by 214.2% in the first quarter. AQR Capital Management LLC now owns 5,385 shares of the biotechnology company’s stock worth $344,000 after buying an additional 3,671 shares during the period. Great Lakes Advisors LLC purchased a new stake in Sarepta Therapeutics during the 1st quarter valued at about $224,000. PNC Financial Services Group Inc. grew its position in Sarepta Therapeutics by 61.8% during the 2nd quarter. PNC Financial Services Group Inc. now owns 3,779 shares of the biotechnology company’s stock worth $65,000 after acquiring an additional 1,444 shares during the last quarter. Geode Capital Management LLC grew its position in Sarepta Therapeutics by 3.0% during the 2nd quarter. Geode Capital Management LLC now owns 1,875,997 shares of the biotechnology company’s stock worth $32,085,000 after acquiring an additional 55,076 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey increased its stake in Sarepta Therapeutics by 4.7% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 34,775 shares of the biotechnology company’s stock worth $595,000 after purchasing an additional 1,573 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.